Something went wrong: t.at is not a function

Sandoz, we provide more than 900 million patient treatments annually, leading to USD 19 billion savings per year for healthcare systems in Europe and the US alone, and generating a total …

Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024. Disclaimer

Login to Sandoz Customer Connect™ Email Address: Password: Login; Forgot Password? > New to Sandoz? Contact Us; FAQ; Terms of Use; Privacy Policy; Returns Policy

Sandoz delivered strong financial results in 2024, underpinned by continued momentum in the biosimilar business and progress in our journey as a standalone company. NET SALES TO …

Sandoz is well positioned to drive sustainable growth and long-term shareholder value through the following six strategic levers:

4 天之前 · Sandoz, we provide more than 900 million patient treatments annually, leading to USD 19 billion savings per year for healthcare systems in Europe and the US alone, and generating …

Sandoz delivered solid financial results in the first half of 2024, meeting key milestones in our biosimilar business and progressing on our journey as a standalone company. The momentum …

Sandoz’s ambition is to be the world’s leading biosimilars and generics company. The total rewards packages allow Sandoz to attract and retain top talent in a highly competitive market. …

At Sandoz, diversity, equity and inclusion are at the heart of all we do, starting at the top of our organization, with women representing 37% of senior leadership, 44% of our Board of